Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Quarterly Earnings Results

Key Points

• Q1 earnings missed: Supernus reported EPS of ($0.04) versus a $0.28 consensus and revenue of $190.8M (vs. $192.9M), leaving a negative net margin of 5.36% despite a 12.26% return on equity.
• Stock and analyst backdrop: Shares rose about 0.8% to $49.03 on above-average volume; the company has a $2.82B market cap, a negative P/E, and an average analyst rating of "Hold" with a $62.17 consensus price target.
• Insider selling: Insiders have sold 120,881 shares worth roughly $6.14M in the past three months, though they still own about 8.8% of the company.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) released its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.32), FiscalAI reports. The company had revenue of $190.80 million during the quarter, compared to analysts' expectations of $192.92 million. Supernus Pharmaceuticals had a negative net margin of 5.36% and a positive return on equity of 12.26%.

Supernus Pharmaceuticals Trading Up 0.8%

Shares of SUPN traded up $0.40 during mid-day trading on Tuesday, hitting $49.03. The company's stock had a trading volume of 1,105,499 shares, compared to its average volume of 695,461. The company's 50-day moving average is $51.14 and its 200-day moving average is $49.90. Supernus Pharmaceuticals has a 52-week low of $29.16 and a 52-week high of $59.68. The firm has a market capitalization of $2.82 billion, a price-to-earnings ratio of -72.10, a PEG ratio of 0.94 and a beta of 0.57.

Analyst Ratings Changes

Several research firms have issued reports on SUPN. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Weiss Ratings reissued a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Sunday, March 8th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Monday, April 27th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Supernus Pharmaceuticals has an average rating of "Hold" and a consensus price target of $62.17.

Insider Transactions at Supernus Pharmaceuticals

In other news, Director Frederick M. Hudson sold 5,369 shares of the company's stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total value of $271,725.09. Following the completion of the sale, the director owned 60,413 shares of the company's stock, valued at approximately $3,057,501.93. This represents a 8.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bethany Sensenig sold 4,475 shares of the company's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $51.01, for a total transaction of $228,269.75. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 120,881 shares of company stock worth $6,139,356. Insiders own 8.80% of the company's stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth approximately $51,000. Raymond James Financial Inc. purchased a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $55,000. Osaic Holdings Inc. lifted its position in Supernus Pharmaceuticals by 211.5% during the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company's stock valued at $63,000 after acquiring an additional 1,328 shares during the last quarter. Vestcor Inc purchased a new stake in Supernus Pharmaceuticals during the third quarter valued at approximately $67,000. Finally, iSAM Funds UK Ltd purchased a new stake in Supernus Pharmaceuticals during the third quarter valued at approximately $128,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.